Micro Labs Recalls Glimepiride Tablets Due to Failed Stability Testing
Micro Labs USA is recalling specific lots of Glimepiride tablets because they failed stability testing. The affected products were distributed in five states.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which is a situation where use of the product could cause temporary or medically reversible health consequences. The source text does not report any illnesses or injuries, and the hazard is related to stability specifications rather than a known acute pathogen or structural defect.
Plain-English summary
Micro Labs USA, Inc. is recalling two lots of Glimepiride tablets, USP 2 mg. The recall was initiated because the products failed to meet stability specifications during testing. The affected products are available in 100-count and 500-count bottles and are prescription-only medications.
The recalled lots are identified by the codes GLBG001 (expiration date 12/14) and GLBG008 (expiration date 06/15). A total of 11,328 bottles were distributed to Connecticut, Florida, Maryland, Mississippi, and New York. The medication was manufactured by Micro Labs Limited in India for Micro Labs USA, Inc. in Princeton, New Jersey.
Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates. If the products are found, they should be returned to the pharmacy or contact Micro Labs USA for further instructions.
The recalled product
- Product
- GLIMEPIRIDE (GLIMEPIRIDE)
- Brand
- GLIMEPIRIDE
- Manufacturer
- Micro Labs Usa, Inc S
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 11,328
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- GLBG001 Exp.12/14
- GLBG008 Exp. 06/15
UPCs (6)
- 0342571100018
- 0342571102012
- 0342571101015
- 0342571104016
- 0342571105013
- 0342571103019
Distribution
Related recalls
Same brand · GLIMEPIRIDE
- ModerateFDA Recalls Glimepiride Tablets for Misprint on Tablet
FDA (Drugs) · 2024-02-14
- ModeratePrescription Glimepiride Tablets Recalled Due to Tablet Misprint
FDA (Drugs) · 2024-02-14
- ModerateFDA Recalls Glimepiride Tablets for Manufacturing Deviations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Drug Glimepiride Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2023-05-03
- HighAccord Healthcare recalls Glimepiride tablets due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Micro Labs Usa, Inc S
See all →- LowMicro Labs Recalls Simvastatin Tablets Due to Impurity Failure
FDA (Drugs) · 2015-03-18
- ModerateMicro Labs Recalls Simvastatin Tablets Due to Impurity Failure
FDA (Drugs) · 2015-03-18
- ModerateMicro Labs Recalls Simvastatin Tablets Due to Impurity Failure
FDA (Drugs) · 2015-03-18
- SevereMicro Labs Recalls Losartan Potassium Tablets for Content Uniformity Failures
FDA (Drugs) · 2014-11-26
- LowMicro Labs Recalls Simvastatin Tablets Due to Impurity Specification Failure
FDA (Drugs) · 2014-11-19
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCiclopirox shampoo recalled after failing impurity specifications at eighteen months
FDA (Drugs) · 2025-12-24